These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 19636335)

  • 21. Premenopausal Osteoporosis.
    Cohen A
    Endocrinol Metab Clin North Am; 2017 Mar; 46(1):117-133. PubMed ID: 28131128
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
    Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
    Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Role of pharmaceutical intervention in the treatment of osteoporosis and prevention of fracture].
    Nakamura T
    Nihon Rinsho; 2009 May; 67(5):903-8. PubMed ID: 19432107
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effect and role of teriparatide in the treatment of osteoporosis].
    Nakamura T
    Clin Calcium; 2012 Mar; 22(3):309-14. PubMed ID: 22370296
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Skeletal response to treatment with teriparatide (TPD) after bisphosphonate in post-menopausal women with osteoporosis and a high prevalence of secondary risk factors in real-life setting of a metabolic bone clinic; effect of age and vitamin D status.
    Mok J; Brown C; Moore AEB; Min SS; Hampson G
    Endocr Res; 2018 Aug; 43(3):195-202. PubMed ID: 29652557
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gender differences in osteoporosis and fractures.
    Cawthon PM
    Clin Orthop Relat Res; 2011 Jul; 469(7):1900-5. PubMed ID: 21264553
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New therapeutic targets for osteoporosis.
    Anagnostis P; Gkekas NK; Potoupnis M; Kenanidis E; Tsiridis E; Goulis DG
    Maturitas; 2019 Feb; 120():1-6. PubMed ID: 30583758
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnosis and Management of Osteoporosis.
    Jeremiah MP; Unwin BK; Greenawald MH; Casiano VE
    Am Fam Physician; 2015 Aug; 92(4):261-8. PubMed ID: 26280231
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Bone anabolic treatment with Teriparatide].
    Lamy O
    Ther Umsch; 2012 Mar; 69(3):187-91. PubMed ID: 22403112
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
    Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
    Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of teriparatide in bisphosphonate-pretreated and treatment-naive patients with osteoporosis at high risk of fracture: Post hoc analysis of a prospective observational study.
    Yoshiki F; Nishikawa A; Taketsuna M; Kajimoto K; Enomoto H
    J Orthop Sci; 2017 Mar; 22(2):330-338. PubMed ID: 28038880
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevention of osteoporotic fractures in the elderly.
    Wilkins CH; Birge SJ
    Am J Med; 2005 Nov; 118(11):1190-5. PubMed ID: 16271899
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [DVO guideline 2006. What changes have there been in the diagnosis, prevention and treatment of osteoporosis?].
    Fassbender WJ; Stumpf UC
    Z Rheumatol; 2006 Sep; 65(5):364-6, 368-9. PubMed ID: 16947038
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Baseline characteristics of postmenopausal women with osteoporosis treated with teriparatide in a real-world setting in Latin America: a subregional analysis from the Asia and Latin America Fracture Observational Study (ALAFOS).
    Cunha-Borges JL; Mier GM; Casas N; Medina A; Molina JF; García ML; Oliveria LG; Caselato MS; Cruz AC; Ippolito V; Flórez S
    Adv Rheumatol; 2019 Nov; 59(1):46. PubMed ID: 31703737
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Measurement of bone mineral density is unnecessary for monitoring of bisphosphonate treatment].
    Nishida A; Ito M
    Clin Calcium; 2011 Jan; 21(1):120-3. PubMed ID: 21187605
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
    Saag KG; Shane E; Boonen S; Marín F; Donley DW; Taylor KA; Dalsky GP; Marcus R
    N Engl J Med; 2007 Nov; 357(20):2028-39. PubMed ID: 18003959
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [FRAX® thresholds to identify people with high or low risk of osteoporotic fracture in Spanish female population].
    Azagra R; Roca G; Martín-Sánchez JC; Casado E; Encabo G; Zwart M; Aguyé A; Díez-Pérez A;
    Med Clin (Barc); 2015 Jan; 144(1):1-8. PubMed ID: 24461732
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [New development in bisphosphonate treatment. Bisphosphonates for the treatment of glucocorticoid-induced osteoporosis].
    Soen S
    Clin Calcium; 2009 Jan; 19(1):44-53. PubMed ID: 19122264
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacologic and nonpharmacologic management of osteoporosis.
    Levine JP
    Clin Cornerstone; 2006; 8(1):40-53. PubMed ID: 17591575
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advances in the medical management of osteoporosis.
    Kates SL; Kates OS; Mendelson DA
    Injury; 2007 Sep; 38 Suppl 3():S17-23. PubMed ID: 17723788
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.